Ru­bius re­sorts to lay­offs and aban­dons its lead pro­grams as its sur­vival strat­e­gy

Four years ago, Cam­bridge-based Ru­bius Ther­a­peu­tics was hav­ing the time of its life. The com­pa­ny, which makes en­gi­neered red cells, was rak­ing in am­ple cash and had en­joyed a $1.8 bil­lion mar­ket val­u­a­tion reg­is­tered at the IPO.

To­day it is a whole dif­fer­ent sto­ry.

Ru­bius has de­cid­ed to scrap two of its lead­ing on­go­ing tri­als, let go of 75% of its work­force and ex­plore the sale of its man­u­fac­tur­ing fa­cil­i­ty in Rhode Is­land, the biotech an­nounced Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER